A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5
Conditions
- Malaria
- Plasmodium Falciparum
Interventions
- BIOLOGICAL: ChAd63 RH5 low dose
- BIOLOGICAL: ChAd63 RH5 full dose
- BIOLOGICAL: MVA RH5 low dose
- BIOLOGICAL: MVA RH5 full dose
Sponsor
University of Oxford
Collaborators